研究单位:[1]Haisco Pharmaceutical Group Co., Ltd.[2]The Fourth Hospital of Hebei Medical University河北医科大学第四医院
研究目的:
This study is a single-center, open, single-arm study, conducted in healthy Chinese populations, and plans to enroll 22 healthy adult subjects (the ratio of either sex is not less than 1/3).